# A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

> **NCT06559163** · PHASE2 · RECRUITING · sponsor: **Zenas BioPharma (USA), LLC** · enrollment: 190 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Obexelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06559163
- **Lead sponsor:** Zenas BioPharma (USA), LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-17
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06559163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06559163, "A Study of Obexelimab in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06559163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*